In our retrospective series of 98 consecutive clear cell renal cell carcinoma (ccRCC), we identified an independent association between PD-L1 immunostaining and non-inactivated VHL ccRCC. In particular wild-type VHL ccRCC all expressed PD-L1. Wild-type VHL ccRCC are a sub-group that are associated with a worse prognosis. These patients with PD-L1 expression may benefit from targeted immunotherapy.
ABSTRACT
Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor that is characterized in most cases by inactivation of the tumor suppressor gene VHL. The VHL/HIF/VEGF pathway thus plays a major role in angiogenesis and is currently targeted by anti-angiogenic therapy. The emergence of resistance is leading to the use of targeted immunotherapy against immune checkpoint PD1/PDL1 that restores antitumor immune response. The correlation between VHL status and PD-L1 expression has been little investigated.
In this study, we retrospectively reviewed 98 consecutive cases of ccRCC and correlated PD-L1 expression by immunohistochemistry (IHC) with clinical data (up to 10-year follow-up), pathological criteria, VEGF, PAR-3, CAIX and PD-1 expressions by IHC and complete VHL status (deletion, mutation and promoter hypermethylation).
PD-L1 expression was observed in 69 ccRCC (70.4%) and the corresponding patients had a worse prognosis, with a median specific survival of 52 months (p=0.03). PD-L1 expression was significantly associated with poor prognostic factors such as a higher ISUP nucleolar grade (p=0.01), metastases at diagnosis (p=0.01), a sarcomatoid component (p=0.04), overexpression of VEGF (p<0.01), and cytoplasmic PAR-3 expression (p=0.01). PD-L1 expression was also associated with dense PD-1 expression (p=0.007) and with ccRCC with 0 or 1 alteration(s) (non-inactivated VHL tumors) (p<0.01) that remained significant after multivariate analysis (p=0.004 and p=0.024, respectively). Interestingly, all wildtype VHL tumors (no VHL gene alteration, 11.2%) expressed PD-L1.
In this study, we found PD-L1 expression to be associated with non-inactivated VHL tumors and in particular wild-type VHL ccRCC which may benefit from therapies inhibiting PD-L1/PD-1.
INTRODUCTION
Clear cell renal cell carcinoma (ccRCC) accounts for approximately 3% of adult cancers and is a very aggressive tumor with a 50% risk of metastases at initial diagnosis or follow-up. 1 The VHL (von Hippel-Lindau) gene, located on chromosome 3p25, is a major tumor suppressor gene involved in ccRCC oncogenesis. 2 Alterations of this gene occur in the majority of ccRCC through mutations or deletions and/or hypermethylation of its promoter 3 .
VHL gene inactivation necessarily involves biallelic alterations in tumor cells, as both first and second "hits" must occur to be inactivated. However, a minority of ccRCC exhibit no or a single allele alteration on the VHL gene. 4 The protein, pVHL, is a component of an E3 ubiquitin-ligase which targets the transcription factor: hypoxia-inducible factor (HIF). 3 The consequence of pVHL impairment is a stabilization of HIF resulting in overexpression of HIF. This leads to the transcription of genes regulated by HIF, such as vascular endothelial growth factor (VEGF) or carbonic anhydrase IX (CAIX). Consequently, VHL is one of the main triggers of the angiogenesis process in ccRCC. 5 Based on an understanding of these mechanisms, therapies targeting angiogenesis emerged in the last decade, significantly improving the prognosis of metastatic ccRCC. 6 However, the response is short-lived due to the development of resistance to these therapeutic agents. The aim of this study was to correlate PD-L1 expression with pathological criteria, expression of VEGF, PAR-3 (partitioning defective 3), CAIX, and PD-1, and complete VHL status in a population of patients with ccRCC and a long-term clinical follow-up of 10 years.
MATERIALS AND METHODS

Patients
Consecutive patients operated for sporadic ccRCC in the Department of Urology at Rennes
Hospital between 2002 and 2005 with a clinical follow-up of up to 10 years were retrospectively included in the study. All patients underwent radical nephrectomy without presurgical medication. The study protocol was approved by the local advisory board and informed consent was received from all patients prior to inclusion in the study.
Tissue sample management
Tumor samples were derived from biological sample processing by the Rennes Hospital 
Pathological analysis
After fresh tissue sampling surgical specimens were formalin-fixed. Paraffin sections were stained with hematoxylin and eosin-safran for light microscopy. antibody, clone 130021, dilution 1:200; R&D Systems, Minneapolis, USA) was assessed by immunohistochemistry as previously described. 4, 14, 15 The cut-off for overexpression was set at 85% of tumor cells for CAIX and 30% for VEGF. 4, 14 Only cytoplasmic PAR-3 expression was considered positive as previously assessed. 15 PD-L1 was considered positive when any membranous or cytoplasmic tumor cell staining was observed. 16 Regarding TILs, expression of CD3 (anti-CD3 antibody, clone SP7, dilution 1:100; Thermo Scientific, Waltham, MA, USA) and CD20 (anti-CD20 antibody, clone L26, dilution 1:25; Dako, Glostrup, Denmark)
was assessed. The inflammatory extent was coded as 1 (sparse lymphocytes in the tumor) or 2 (marked dense lymphocytes or lymphoid nodules). Expression of PD-1 (anti-PD-1 antibody, clone NAT105, dilution 1:50; Abcam, Cambridge, UK) in TILs was scored as absent, rare, moderate or marked dense. Absence or rare density was considered negative whereas moderate or marked density was considered positive for statistical analysis.
VHL gene analysis
We determined the complete VHL status for each tumor by analyzing VHL gene mutation, deletion and promoter methylation. Four primers pairs were designed (Primer3 software, Whitehead Research Institute, Cambridge, MA), to amplify two overlapping fragments for exon 1 (1A and 1B) and one fragment for each of exons 2 and 3 (Eurogentech, Belgium), covering part of the VHL 5'UTR, the entire coding sequence and exon-intron junctions (VHL Genbank accession AF010238). The 4 primers are presented in Table I (MLPA) analysis using the SALSA MLPA P016B VHL probe kit and SALSA MS-MLPA kit, respectively, as previously described. 4 As VHL functions as a tumor suppressor gene, impairments necessarily involve biallelic alterations in tumor cells as two hits are needed for inactivation to occur.
Statistical analysis
χ², Fisher's exact and Mann-Whitney tests were performed to compare qualitative and quantitative parameters between the groups with and without PD-L1 expression, respectively.
A logistic regression multivariate analysis was then performed using all significant variables from the univariate analysis (p<0.05). Cancer specific survival (CSS) according to PD-L1 expression was calculated from nephrectomy to death from cancer and Kaplan-Meier curves were compared by log-rank test. All p-values were 2-sided, and p-values less than 0.05 were considered statistically significant. All statistical analyses (AP) were performed using Stata 14.1 (StataCorp, College Station, TX, USA) software.
RESULTS
Patients and pathological parameters
The study retrospectively included 98 patients according to participant flow diagram ( Figure   I , supplementary figures). The median age at diagnosis was 64 years (40-84). Sixty-nine patients (70.4%) had an ECOG performance status of 0. In 11 cases (11.2%), nodal invasion was present at diagnosis and in 23 cases (23.5%) patients had synchronous metastases. The mean tumor size was 7.3 cm +/-3.4 cm with tumors ranging from 1.5 to 18 cm. The population characteristics and pathological parameters are summarized in Table 1 . Table II (supplementary tables) details characteristics of metastatic patients.
Genetic and epigenetic VHL gene alteration
All patients tested negative for germline mutations. A VHL gene mutation was found in 68 cases (69.4%) and detailed in Table III Moderate or dense expression of PD-1 and the niVHL gene was significantly associated with PD-L1 expression in the multivariate analysis (p=0.004 and p=0.024, respectively).
Correlation between PD-L1 expression and survival
The progression of patients in the PD-L1 expression subgroup differed in comparison to patients with no PD-L1 expression in their tumors. The survival curves of the two subgroups are shown in Figure 3 . Patients with PD-L1 expression had a worse prognosis with a median specific survival of 52 months from nephrectomy compared to patients with no PD-L1 expression for whom the median specific survival time was not reached (p=0.030).
DISCUSSION
In our study, we correlated PD-L1 expression by IHC with pathological criteria, expression of VEGF, PAR-3, CAIX, and PD-1, and complete VHL status in a large series of 98 patients with ccRCC and a long-term clinical follow-up of up to 10 years.
As previously reported for ccRCC, in our series PD-L1 expression was associated with poor prognostic factors such as tumor stage, ISUP nucleolar grade, sarcomatoid component, dense PD-1 expression and VEGF expression. 8, 10, 17-19 PD-L1 was also associated with cytoplasmic PAR-3 protein expression which was previously identified as a poor prognostic factor in ccRCC. 15 Furthermore, as expected, patients with PD-L1 expression in ccRCC samples had a worse clinical outcome. 8 As commonly reported, PD-L1 expression was associated with sarcomatoid components.
19, 20
For the first time, we found an association between PD-L1 expression and cytoplasmic PAR-3 expression. PAR-3 is a crucial component of partitioning-defective complex proteins that controls cell polarity and contributes to cell migration and cancer cell epithelial-tomesenchymal transition (EMT). 21 PD-L1 expression associated with both sarcomatoid components and PAR-3 expression suggested potential EMT involvement in ccRCC.
Recently, PD-L1 expression was reported to induce EMT in renal cell carcinoma through activation of SREBP-1c, a key transcription factor for lipogenesis genes. 22 Two general mechanisms for the regulation of PD-L1 by tumor cells have emerged, namely innate immune resistance and adaptive immune resistance. 23 For some tumors, it has been
shown that PD-L1 expression is driven by constitutive oncogenic signaling pathways in tumor cells such as PI3K-AKT and MAPK pathways and is termed innate or constitutive immune resistance. 24, 25 A second alternative mechanism for PD-L1 regulation in tumor cells reflects 26 In our series this mechanism is illustrated by dense PD-1 expression independently associated with PD-L1 expression.
For the first time, we correlated PD-L1 expression by IHC with VHL complete status including VHL gene locus deletion, VHL mutation and promoter hypermethylation. In our study, PD-L1 expression was independently associated with a niVHL status defined by 0 or 1 alterations of the VHL gene. As a tumor suppressor gene, VHL requires at least two events, one on each allele, to be inactivated as it is not a haploinsufficient tumor-suppressor gene. inactivation through HIF-2α. 28 The difference in their conclusions may be due to population variations. In their study, 32 patients were retrospectively included: 21 patients with sporadic ccRCC and 11 with VHL-tumor associated ccRCC. Only one patient (3.1%) had no VHL gene alteration at all. In our series, sporadic ccRCC was an inclusion criterion and VHL-tumor associated ccRCC cases were excluded. Among the 98 patients included, 11 patients (11.2%) had a wtVHL tumor with no VHL gene alteration.
In our study, wtVHL ccRCC were particularly associated with PD-L1 expression. These results support the theory of alternative oncogenic pathways in ccRCC leading to PD-L1 overexpression despite HIF degradation due to the presence of an activated VHL protein 
CONCLUSION
For the first time, we found PD-L1 expression by IHC to be associated with niVHL tumors, and in particular with wtVHL ccRCC. These tumors may benefit from therapies inhibiting PD-L1/PD-1. 
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